{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:44:40Z","timestamp":1793882680691,"version":"4.7.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03834-x","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:23:02Z","timestamp":1751383382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab"],"prefix":"10.1186","volume":"23","author":[{"given":"Satoshi","family":"Mii","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenichi","family":"Morise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Horiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"3834_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet"},{"key":"3834_CR2","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S, Chen L-T, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 2022;1:EVIDoa2200015.","journal-title":"NEJM Evid"},{"key":"3834_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S, Niger M, Lavacchi D, Pressiani T, Lucchetti J, Giordano G, Pretta A, Tamburini E. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int. 2023;43:1803\u201312.","journal-title":"Liver Int"},{"key":"3834_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11523-024-01044-1","volume":"19","author":"A Olkus","year":"2024","unstructured":"Olkus A, Tomczak A, Berger AK, Rauber C, Puchas P, Wehling C, Longerich T, Mehrabi A, Chang DH, Liermann J, Sch\u00e4fer S, Pfeiffenberger J, J\u00e4ger D, Michl P, Springfeld C, Dill MT. Durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer: an exploratory analysis of Real-World data. Target Oncol. 2024;19:213\u201321.","journal-title":"Target Oncol"},{"key":"3834_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","volume":"71","author":"P Bertuccio","year":"2019","unstructured":"Bertuccio P, Malvezzi M, Carioli G, Hashim D, Boffetta P, El-Serag HB, La Vecchia C, Negri E. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71:104\u201314.","journal-title":"J Hepatol"},{"key":"3834_CR6","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1080\/17474124.2021.1991313","volume":"15","author":"M Rimini","year":"2021","unstructured":"Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol. 2021;15:1367\u201383.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3834_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/jjco\/hyad133","volume":"54","author":"R Shimoyama","year":"2024","unstructured":"Shimoyama R, Imamura Y, Uryu K, Mase T, Taguri M, Okuda T, Fujimura Y, Hayashi M, Tanaka S, Sawamukai K, Minami H. Real-world treatment outcomes of metastatic biliary tract cancer patients in Japan: the Tokushukai REAl-world data project 04 (TREAD 04). Jpn J Clin Oncol. 2024;54:70\u201380.","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl 1","key":"3834_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19\u201331.","journal-title":"Liver Int"},{"key":"3834_CR9","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s00595-006-3276-8","volume":"36","author":"WS Lee","year":"2006","unstructured":"Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006;36:892\u20137.","journal-title":"Surg Today"},{"issue":"Suppl 1","key":"3834_CR10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/liv.14086","volume":"39","author":"A Forner","year":"2019","unstructured":"Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvis\u00e9 M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98\u2013107.","journal-title":"Liver Int"},{"key":"3834_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Ilyas SI, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3834_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000513969","volume":"37","author":"A Vogel","year":"2021","unstructured":"Vogel A, Saborowski A. Current and future systemic therapies in biliary tract Cancer. Visc Med. 2021;37:32\u20138.","journal-title":"Visc Med"},{"key":"3834_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bpg.2015.02.007","volume":"29","author":"UP Neumann","year":"2015","unstructured":"Neumann UP, Schmeding M. Role of surgery in cholangiocarcinoma: from resection to transplantation. Best Pract Res Clin Gastroenterol. 2015;29:295\u2013308.","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"3834_CR14","doi-asserted-by":"crossref","unstructured":"Woods E, Le D, Jakka BK, Manne A. Changing landscape of systemic therapy in biliary tract Cancer. Cancers (Basel). 2022;14.","DOI":"10.3390\/cancers14092137"},{"key":"3834_CR15","first-page":"490","volume":"11","author":"W Zeng","year":"2023","unstructured":"Zeng W, Mao R, Zhang Z, Chen X. Combination therapies for advanced biliary tract Cancer. J Clin Transl Hepatol. 2023;11:490\u2013501.","journal-title":"J Clin Transl Hepatol"},{"key":"3834_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and Meta-analysis. JAMA Surg. 2014;149:565\u201374.","journal-title":"JAMA Surg"},{"key":"3834_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2022.09.004","volume":"78","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Khalil DN, Fabris L, Abou-Alfa GK. Rational development of combination therapies for biliary tract cancers. J Hepatol. 2023;78:217\u201328.","journal-title":"J Hepatol"},{"key":"3834_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","volume":"103","author":"T Okusaka","year":"2010","unstructured":"Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469\u201374.","journal-title":"Br J Cancer"},{"key":"3834_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"3834_CR20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J. RECIST 1.1\u2013Standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur J Cancer. 2016;62:138\u201345.","journal-title":"Eur J Cancer"},{"key":"3834_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018ezr\u2019for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3834_CR22","doi-asserted-by":"crossref","unstructured":"Lagenfelt H, Blomstrand H, Elander NO. Real-World evidence on palliative gemcitabine and oxaliplatin (GemOx) combination chemotherapy in advanced biliary tract Cancer. Cancers (Basel). 2021;13.","DOI":"10.3390\/cancers13143507"},{"key":"3834_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00535-018-1518-3","volume":"54","author":"Y Suzuki","year":"2019","unstructured":"Suzuki Y, Kan M, Kimura G, Umemoto K, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, Imaoka H, Ohno I, Mitsunaga S, Ikeda M. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. J Gastroenterol. 2019;54:281\u201390.","journal-title":"J Gastroenterol"},{"key":"3834_CR24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.21037\/jgo.2017.03.06","volume":"8","author":"MK Doherty","year":"2017","unstructured":"Doherty MK, McNamara MG, Aneja P, McInerney E, Moignard S, Horgan AM, Jiang H, Panzarella T, Jang R, Dhani N, Hedley D, Knox JJ. Long term responders to palliative chemotherapy for advanced biliary tract cancer. J Gastrointest Oncol. 2017;8:352\u201360.","journal-title":"J Gastrointest Oncol"},{"key":"3834_CR25","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/bjc.2016.64","volume":"114","author":"J Bridgewater","year":"2016","unstructured":"Bridgewater J, Lopes A, Palmer D, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Valle J, Wasan H. Quality of life, long-term survivors and long-term outcome from the ABC-02 study. Br J Cancer. 2016;114:965\u201371.","journal-title":"Br J Cancer"},{"key":"3834_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00280-009-1011-z","volume":"65","author":"J Furuse","year":"2009","unstructured":"Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer. Cancer Chemother Pharmacol. 2009;65:113\u201320.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3834_CR27","first-page":"1654","volume":"52","author":"T Saisho","year":"2005","unstructured":"Saisho T, Okusaka T, Ueno H, Morizane C, Okada S. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy. Hepatogastroenterology. 2005;52:1654\u20138.","journal-title":"Hepatogastroenterology"},{"key":"3834_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000318020","volume":"79","author":"E Suzuki","year":"2010","unstructured":"Suzuki E, Furuse J, Ikeda M, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C, Kondo S, Shimizu S, Kojima Y, Hagihara A. Treatment efficacy\/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases. Oncology. 2010;79:39\u201345.","journal-title":"Oncology"},{"key":"3834_CR29","doi-asserted-by":"publisher","first-page":"4148","DOI":"10.1002\/cncr.24472","volume":"115","author":"I Park","year":"2009","unstructured":"Park I, Lee JL, Ryu MH, Kim TW, Sook Lee S, Hyun Park D, Soo Lee S, Wan Seo D, Koo Lee S, Kim MH. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer. 2009;115:4148\u201355.","journal-title":"Cancer"},{"key":"3834_CR30","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.ejca.2014.02.015","volume":"50","author":"MG McNamara","year":"2014","unstructured":"McNamara MG, Templeton AJ, Maganti M, Walter T, Horgan AM, McKeever L, Min T, Amir E, Knox JJ. Neutrophil\/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50:1581\u20139.","journal-title":"Eur J Cancer"},{"key":"3834_CR31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.4143\/crt.2016.538","volume":"49","author":"HS Park","year":"2017","unstructured":"Park HS, Park JS, Chun YJ, Roh YH, Moon J, Chon HJ, Choi HJ, Park JS, Lee DK, Lee SJ, Yoon DS, Jeung HC. Prognostic factors and scoring model for survival in metastatic biliary tract Cancer. Cancer Res Treat. 2017;49:1127\u201339.","journal-title":"Cancer Res Treat"},{"key":"3834_CR32","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1093\/annonc\/mdv253","volume":"26","author":"T Grenader","year":"2015","unstructured":"Grenader T, Nash S, Plotkin Y, Furuse J, Mizuno N, Okusaka T, Wasan H, Valle J, Bridgewater J. Derived neutrophil lymphocyte ratio May predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies. Ann Oncol. 2015;26:1910\u20136.","journal-title":"Ann Oncol"},{"key":"3834_CR33","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/annonc\/mdv483","volume":"27","author":"J Bridgewater","year":"2016","unstructured":"Bridgewater J, Lopes A, Wasan H, Malka D, Jensen L, Okusaka T, Knox J, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, McNamara MG, Valle JW. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016;27:134\u201340.","journal-title":"Ann Oncol"},{"key":"3834_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00280-017-3353-2","volume":"80","author":"BJ Kim","year":"2017","unstructured":"Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Park JH, Cho H, Ryoo BY, Chang HM. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol. 2017;80:209\u201315.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3834_CR35","doi-asserted-by":"publisher","first-page":"996","DOI":"10.21037\/jgo.2016.09.10","volume":"7","author":"R Agarwal","year":"2016","unstructured":"Agarwal R, Sendilnathan A, Siddiqi NI, Gulati S, Ghose A, Xie C, Olowokure OO. Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the united States. J Gastrointest Oncol. 2016;7:996\u20131003.","journal-title":"J Gastrointest Oncol"},{"key":"3834_CR36","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88:218\u201330.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3834_CR37","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124.","journal-title":"J Natl Cancer Inst"},{"key":"3834_CR38","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860\u20137.","journal-title":"Nature"},{"key":"3834_CR39","doi-asserted-by":"publisher","first-page":"36857","DOI":"10.18632\/oncotarget.16143","volume":"8","author":"H Tang","year":"2017","unstructured":"Tang H, Lu W, Li B, Li C, Xu Y, Dong J. Prognostic significance of neutrophil-to-lymphocyte ratio in biliary tract cancers: a systematic review and meta-analysis. Oncotarget. 2017;8:36857\u201368.","journal-title":"Oncotarget"},{"key":"3834_CR40","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1038\/sj.bjc.6601705","volume":"90","author":"EY Lin","year":"2004","unstructured":"Lin EY, Pollard JW. Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer. 2004;90:2053\u20138.","journal-title":"Br J Cancer"},{"key":"3834_CR41","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.4049\/jimmunol.139.7.2406","volume":"139","author":"A el-Hag","year":"1987","unstructured":"el-Hag A, Clark RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J Immunol. 1987;139:2406\u201313.","journal-title":"J Immunol"},{"key":"3834_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1080\/07357907.2019.1639057","volume":"37","author":"X Xie","year":"2019","unstructured":"Xie X, Liu J, Yang H, Chen H, Zhou S, Lin H, Liao Z, Ding Y, Ling L, Wang X. Prognostic value of baseline Neutrophil-to-Lymphocyte ratio in outcome of immune checkpoint inhibitors. Cancer Invest. 2019;37:265\u201374.","journal-title":"Cancer Invest"},{"key":"3834_CR43","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","volume":"12","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, Weiss K, Kelly DW, Adusumilli PS, Paik PK, Plitas G, Ladanyi M, Postow MA, Ariyan CE, Shoushtari AN, Balachandran VP, Hakimi AA, Crago AM, Long Roche KC, Smith JJ, Ganly I, Wong RJ, Patel SG, Shah JP, Lee NY, Riaz N, Wang J, Zehir A, Berger MF, Chan TA, Seshan VE, Morris LGT. Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun. 2021;12:729.","journal-title":"Nat Commun"},{"key":"3834_CR44","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.21873\/anticanres.15781","volume":"42","author":"E Booka","year":"2022","unstructured":"Booka E, Kikuchi H, Haneda R, Soneda W, Kawata S, Murakami T, Matsumoto T, Hiramatsu Y, Takeuchi H. Neutrophil-to-Lymphocyte ratio to predict the efficacy of immune checkpoint inhibitor in upper Gastrointestinal Cancer. Anticancer Res. 2022;42:2977\u201387.","journal-title":"Anticancer Res"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03834-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03834-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:04:11Z","timestamp":1751385851000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03834-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3834"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03834-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Individual identifying data were not included in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"statement: This study was approved by the institutional review board of Fujita Health University (HM24-011). This study was also performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Informed consent for this study was obtained through an opt-out method.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"258"}}